Effects of Semaglutide on Nicotine Intake

NCT05530577 on ClinicalTrials.gov · last registry update 2025-08-22

A small phase 2 — 24 participants, against a typical 110. The sponsor logged completion for 13 May 2024. Primary outcome, as filed: Change in Nicotine Self-Administration. semaglutide is approved in the US, but not for substance use — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P2
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: University of North Carolina, Chapel Hill
Sponsor type: Other
Enrollment: 24
Started: 2022-10-07
Primary completion: 2024-05-13 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in Nicotine Self-Administration

Conditions studied

Tobacco Use Disorder · Nicotine Addiction

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.